LUCD Share Price Performance
US$1.06
0.08 (8.26%)
47.0% undervalued intrinsic discount
US$2.00
Fair Value
Price US$1.06
AnalystLowTarget US$2.00
AnalystHighTarget US$7.34
AnalystConsensusTarget US$3.79
Fair ValueUS$2.00
Share Pricen/a
Lucid Diagnostics Inc. Stock Price
- 3 Narratives written by author
- 0 Comments on narratives written by author
- 6 Fair Values set on narratives written by author
LUCD Community Narratives
AN
Fair Value US$2 47.0% undervalued intrinsic discount
Medicare Coverage Delays Will Exacerbate Cash Burn Yet Yield Recovery
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
Fair Value US$7.34 85.6% undervalued intrinsic discount
Aging Demographics And Medicare Coverage Will Spur Early Detection
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
Fair Value US$3.63 70.8% undervalued intrinsic discount
Medicare Coverage And Health Partnerships Will Unlock Future Potential
0users have liked this narrative
0users have commented on this narrative
5users have followed this narrative
Aging Demographics And Medicare Coverage Will Spur Early Detection
Key Takeaways Accelerating insurance coverage, including Medicare and private payers, signals a tipping point for rapid test adoption and transformative revenue and margin growth. Scalable health system integration and operational infrastructure position Lucid to leverage rising demand for preventive diagnostics, supporting sustained, profitable expansion.Read more
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
US$7.34
85.6% undervalued intrinsic discount
AnalystHighTarget Fair Value
Revenue
150% p.a.
Profit Margin
12.32%
Future PE
136.7x
Price in 2028
US$5.1
Medicare Coverage And Health Partnerships Will Unlock Future Potential
Key Takeaways Expanding insurance coverage and Medicare access are poised to drive significant revenue growth and improve payment predictability. Strategic health system partnerships and greater medical guideline support position the company for scalable adoption and long-term market expansion.Read more
0users have liked this narrative
0users have commented on this narrative
5users have followed this narrative
AN
US$3.63
70.8% undervalued intrinsic discount
AnalystConsensusTarget Fair Value
Revenue
99% p.a.
Profit Margin
12.49%
Future PE
131.12x
Price in 2028
US$2.52
Medicare Coverage Delays Will Exacerbate Cash Burn Yet Yield Recovery
Key Takeaways Lucid faces significant risks from slow clinician adoption, uncertain reimbursement, and evolving regulatory landscapes, potentially delaying revenue growth and path to profitability. Ongoing high cash burn and potential for increased dilution or debt could constrain long-term financial stability, despite a favorable market outlook for early cancer detection.Read more
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
US$2
47.0% undervalued intrinsic discount
AnalystLowTarget Fair Value
Revenue
64% p.a.
Profit Margin
12.49%
Future PE
130.85x
Price in 2028
US$1.39
Trending Discussion
Recently Updated Narratives
AN
Medicare Coverage Delays Will Exacerbate Cash Burn Yet Yield Recovery
Fair Value: US$2 47.0% undervalued intrinsic discount
0 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Aging Demographics And Medicare Coverage Will Spur Early Detection
Fair Value: US$7.34 85.6% undervalued intrinsic discount
0 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Medicare Coverage And Health Partnerships Will Unlock Future Potential
Fair Value: US$3.63 70.8% undervalued intrinsic discount
5 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Lucid Diagnostics Inc. Key Details
Last Reported Earnings
Sep 30, 2025
Next Reporting Earnings
n/a
- -0.50
- -58.10%
- -1,496.79%
- 86.3%
About LUCD
- Founded
- 2018
- Employees
- 72
- CEO
- WebsiteView website
Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company in the United States. The company focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma. Its flagship product, the EsoGuard Esophageal DNA Test performed on samples collected with the EsoCheck Esophageal Cell collection device, a testing tool with the goal of preventing EAC deaths through early detection of esophageal precancer in at-risk GERD patients. The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. operates as a subsidiary of PAVmed Inc.
